Positron emission tomography (PET) measurements of striatal D2 receptors in untreated Parkinson's disease patients with follow-up after 6 and 12 months' treatment with SINEMET® or SINEMET® CR
Identifieur interne : 001F43 ( Main/Exploration ); précédent : 001F42; suivant : 001F44Positron emission tomography (PET) measurements of striatal D2 receptors in untreated Parkinson's disease patients with follow-up after 6 and 12 months' treatment with SINEMET® or SINEMET® CR
Auteurs : Ryan J. Uitti [Canada] ; Francois J. G. Vingerhoets [Canada] ; Margo Hayward [Canada] ; Sandra Cooper [Canada] ; Barry J. Snow [Canada]Source :
- Parkinsonism and Related Disorders [ 1353-8020 ] ; 1996.
Abstract
Untreated Parkinson's disease (FD) patients typically demonstrate an upregulation in striatal D2 receptor binding. Reduced D2 binding is found in levodopa-treated patients with a fluctuating response to this drug. Using PET and 11C-raclopride, we determined striatal:background uptake ratios to provide a measure of D2 receptor binding in 10 untreated, newly diagnosed PD patients who were treated subsequently with levodopa for 1 yr. At baseline, we found increased striatal D2 receptor uptake ratios in patients (3.89) in comparison to normal controls (3.22; p < 0.02). Furthermore, the ratio between caudate and putamen D2 uptake was significantly reduced in patients (0.86 vs. 0.98 in normals, p < 0.01). Patients were subsequently randomized to treatment with either SINEMET® (300 mg of levodopa/d) or SINEMET® CR (400 mg of levodopa/d). Patients in both groups received similar symptomatic benefit following treatment, and none developed motor fluctuations. All patients were rescanned after 6 months of treatment. There were no significant differences in striatal (or caudate and putamen considered singly) raclopride binding between the first and 6 month post-treatment scans. Similarly, there were no significant differences between pre- and 6 month post-treatment scans on the basis of levodopa preparations. Patients were subsequently treated with the other Sinemet preparation for another 6 month period before rescanning. Again, no differences in raclopride binding were found compared to pre-treatment or between type of levodopa preparation. We conclude that there is no evidence for downregulation of D2 receptor binding after 1 yr of low-dose levodopa therapy in patients who receive symptomatic benefit without motor fluctuations, regardless of type of preparation. Follow-up of such individuals may permit determination of when and in what context D2 receptor downregulation occurs.
Url:
DOI: 10.1016/S1353-8020(96)00038-7
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Positron emission tomography (PET) measurements of striatal D2 receptors in untreated Parkinson's disease patients with follow-up after 6 and 12 months' treatment with SINEMET® or SINEMET® CR</title><author><name sortKey="Uitti, Ryan J" sort="Uitti, Ryan J" uniqKey="Uitti R" first="Ryan J." last="Uitti">Ryan J. Uitti</name></author><author><name sortKey="Vingerhoets, Francois J G" sort="Vingerhoets, Francois J G" uniqKey="Vingerhoets F" first="Francois J. G." last="Vingerhoets">Francois J. G. Vingerhoets</name></author><author><name sortKey="Hayward, Margo" sort="Hayward, Margo" uniqKey="Hayward M" first="Margo" last="Hayward">Margo Hayward</name></author><author><name sortKey="Cooper, Sandra" sort="Cooper, Sandra" uniqKey="Cooper S" first="Sandra" last="Cooper">Sandra Cooper</name></author><author><name sortKey="Snow, Barry J" sort="Snow, Barry J" uniqKey="Snow B" first="Barry J." last="Snow">Barry J. Snow</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:9715E4F08D140C177A4E36B574B6587F37D3814F</idno><date when="1997" year="1997">1997</date><idno type="doi">10.1016/S1353-8020(96)00038-7</idno><idno type="url">https://api.istex.fr/document/9715E4F08D140C177A4E36B574B6587F37D3814F/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">001F37</idno><idno type="wicri:Area/Main/Curation">001C43</idno><idno type="wicri:Area/Main/Exploration">001F43</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">Positron emission tomography (PET) measurements of striatal D2 receptors in untreated Parkinson's disease patients with follow-up after 6 and 12 months' treatment with SINEMET® or SINEMET® CR</title><author><name sortKey="Uitti, Ryan J" sort="Uitti, Ryan J" uniqKey="Uitti R" first="Ryan J." last="Uitti">Ryan J. Uitti</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Neurodegenerative Disorders Centre, Vancouver Hospital and Health Sciences Centre, University of British Columbia, Vancouver, British Columbia</wicri:regionArea><wicri:noRegion>British Columbia</wicri:noRegion></affiliation></author><author><name sortKey="Vingerhoets, Francois J G" sort="Vingerhoets, Francois J G" uniqKey="Vingerhoets F" first="Francois J. G." last="Vingerhoets">Francois J. G. Vingerhoets</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Neurodegenerative Disorders Centre, Vancouver Hospital and Health Sciences Centre, University of British Columbia, Vancouver, British Columbia</wicri:regionArea><wicri:noRegion>British Columbia</wicri:noRegion></affiliation></author><author><name sortKey="Hayward, Margo" sort="Hayward, Margo" uniqKey="Hayward M" first="Margo" last="Hayward">Margo Hayward</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Neurodegenerative Disorders Centre, Vancouver Hospital and Health Sciences Centre, University of British Columbia, Vancouver, British Columbia</wicri:regionArea><wicri:noRegion>British Columbia</wicri:noRegion></affiliation></author><author><name sortKey="Cooper, Sandra" sort="Cooper, Sandra" uniqKey="Cooper S" first="Sandra" last="Cooper">Sandra Cooper</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Neurodegenerative Disorders Centre, Vancouver Hospital and Health Sciences Centre, University of British Columbia, Vancouver, British Columbia</wicri:regionArea><wicri:noRegion>British Columbia</wicri:noRegion></affiliation></author><author><name sortKey="Snow, Barry J" sort="Snow, Barry J" uniqKey="Snow B" first="Barry J." last="Snow">Barry J. Snow</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Neurodegenerative Disorders Centre, Vancouver Hospital and Health Sciences Centre, University of British Columbia, Vancouver, British Columbia</wicri:regionArea><wicri:noRegion>British Columbia</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Parkinsonism and Related Disorders</title><title level="j" type="abbrev">PRD</title><idno type="ISSN">1353-8020</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1996">1996</date><biblScope unit="volume">3</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="43">43</biblScope><biblScope unit="page" to="46">46</biblScope></imprint><idno type="ISSN">1353-8020</idno></series><idno type="istex">9715E4F08D140C177A4E36B574B6587F37D3814F</idno><idno type="DOI">10.1016/S1353-8020(96)00038-7</idno><idno type="PII">S1353-8020(96)00038-7</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1353-8020</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Untreated Parkinson's disease (FD) patients typically demonstrate an upregulation in striatal D2 receptor binding. Reduced D2 binding is found in levodopa-treated patients with a fluctuating response to this drug. Using PET and 11C-raclopride, we determined striatal:background uptake ratios to provide a measure of D2 receptor binding in 10 untreated, newly diagnosed PD patients who were treated subsequently with levodopa for 1 yr. At baseline, we found increased striatal D2 receptor uptake ratios in patients (3.89) in comparison to normal controls (3.22; p < 0.02). Furthermore, the ratio between caudate and putamen D2 uptake was significantly reduced in patients (0.86 vs. 0.98 in normals, p < 0.01). Patients were subsequently randomized to treatment with either SINEMET® (300 mg of levodopa/d) or SINEMET® CR (400 mg of levodopa/d). Patients in both groups received similar symptomatic benefit following treatment, and none developed motor fluctuations. All patients were rescanned after 6 months of treatment. There were no significant differences in striatal (or caudate and putamen considered singly) raclopride binding between the first and 6 month post-treatment scans. Similarly, there were no significant differences between pre- and 6 month post-treatment scans on the basis of levodopa preparations. Patients were subsequently treated with the other Sinemet preparation for another 6 month period before rescanning. Again, no differences in raclopride binding were found compared to pre-treatment or between type of levodopa preparation. We conclude that there is no evidence for downregulation of D2 receptor binding after 1 yr of low-dose levodopa therapy in patients who receive symptomatic benefit without motor fluctuations, regardless of type of preparation. Follow-up of such individuals may permit determination of when and in what context D2 receptor downregulation occurs.</div></front></TEI><affiliations><list><country><li>Canada</li></country></list><tree><country name="Canada"><noRegion><name sortKey="Uitti, Ryan J" sort="Uitti, Ryan J" uniqKey="Uitti R" first="Ryan J." last="Uitti">Ryan J. Uitti</name></noRegion><name sortKey="Cooper, Sandra" sort="Cooper, Sandra" uniqKey="Cooper S" first="Sandra" last="Cooper">Sandra Cooper</name><name sortKey="Hayward, Margo" sort="Hayward, Margo" uniqKey="Hayward M" first="Margo" last="Hayward">Margo Hayward</name><name sortKey="Snow, Barry J" sort="Snow, Barry J" uniqKey="Snow B" first="Barry J." last="Snow">Barry J. Snow</name><name sortKey="Vingerhoets, Francois J G" sort="Vingerhoets, Francois J G" uniqKey="Vingerhoets F" first="Francois J. G." last="Vingerhoets">Francois J. G. Vingerhoets</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001F43 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001F43 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:9715E4F08D140C177A4E36B574B6587F37D3814F
|texte= Positron emission tomography (PET) measurements of striatal D2 receptors in untreated Parkinson's disease patients with follow-up after 6 and 12 months' treatment with SINEMET® or SINEMET® CR
}}
| This area was generated with Dilib version V0.6.23. |  |